Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Biopsy proven EBV(+) or KSHV(+) malignancy~* Relapsed/refractory disease failing \> 2 prior therapies~* Measurable, non-bony disease (at least one lesion on radiographic or physical exam assessment measuring \> 2 cm in longest axis)~* KS patients with skin-only disease must have cutaneous lesions amenable to four 3 mm punch biopsies during the course of the study~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~* Life expectancy of greater than 12 weeks~* Patients must be able to lie flat for at least 60 minutes and fit on a PET-CT scanner~* Ability to comply with an oral drug regimen~* Females of childbearing potential must have a negative pregnancy test at screening~* Patients must have normal organ and marrow function as defined below within 14 days of study entry~Exclusion Criteria:~* Patients with HIV-associated primary central nervous system lymphoma~* Radiotherapy or chemotherapy ending within 14 days of study enrollment~* Patients currently on other protease inhibitors~* Chronic diarrhea~* Acute, active infection within 14 days of enrollment~* Patients on active treatment for hypo- or hyperthyroidism~* End-stage liver disease unrelated to tumor~* Hepatitis B or hepatitis C infection~* Use of any other type of investigational agent or treatment concurrently or within 28 days before the first dose of study treatment~* History of iodine hypersensitivity~* Females who are pregnant or breastfeeding~* Physical or psychiatric conditions that in the estimation of the investigator place the patient at high risk of toxicity, non-compliance, or inability to complete the study requirements~* Use of drugs to treat or prevent herpesvirus infections~* Essential medication that is known to interact with nelfinavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nelfinavir (Type: EXPERIMENTAL): Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).